Product overview

Zycortal® is a prolonged-release suspension used as replacement therapy for mineralocorticoid deficiency in dogs with primary hypoadrenocorticism.  It is the only veterinary licensed product in New Zealand for the treatment of canine Addison's disease.

Zycortal® contains desoxycortone pivalate (DOCP), which is a pure mineralocorticoid hormone that regulates electrolytes and water balance, which are impaired in cases of mineralocorticoid deficiency in Addison’s disease.  Unlike some other mineralocorticoids, DOCP has limited glucocorticoid activity, allowing the independent dose tiltration of mineralocorticoid without the risk of inducing marked side effects from glucocorticoid oversupplementation eg polyuria, polydipsia, polyphagia and muscle atrophy

Addison’s disease resembles many other illnesses so it can be challenging to diagnose.  Being more aware of this condition is half the battle.